
-
Mustang Bio Inc NasdaqCM:MBIO Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases. It develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-101, an IL13Ra2 CAR T cell program for glioblastoma; and MB-108 for the treatment of herpes simplex virus-1 oncolytic virus C134. The company was incorporated in 2015 and is headquartered in Waltham, Massachusetts.
Location: 95 Sawyer Road, Waltham, MA, 02453, United States | Website: https://www.mustangbio.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-8.365M
Cash
14.23M
Avg Qtr Burn
-1.87M
Short % of Float
2.14%
Insider Ownership
10.94%
Institutional Own.
6.88%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
MB-107 Details X-Linked severe combined immunodeficiency | Phase 2 Update | |
MB-207 Details X-Linked severe combined immunodeficiency, Myelofibrosis | Phase 2 Update | |
MB-106 (CD20) (Mustang Multicenter) Details Chronic lymphocytic leukemia, Non-Hodgkin lymphoma, Cancer, Lymphoma | Phase 2 Initiation | |
MB-106 (CD20) (Fred Hutch) Details Lymphoma, Chronic lymphocytic leukemia, Non-Hodgkin lymphoma, Epstein-Barr virus, Multiple sclerosis, Cancer, Waldenstrom macroglobulinemia | Phase 1/2 Update | |
MB-101 (IL-13Ra2) + MB-108 Details Medulloblastoma, Ependymoma, Glioblastoma, Leptomeningeal brain tumors | Phase 1 Initiation | |
MB-104 Details Multiple myeloma, Cancer, Solid tumor/s | Failed Discontinued | |
MB-102 (CD123) Details High risk myelodysplastic syndromes , Blastic plasmacytoid dendritic cell neoplasm, Acute myeloid leukemia, Cancer | Failed Discontinued | |
MB-110 (LV-RAG1) Details Severe combined immunodeficiency due to complete RAG1/2 deficiency | Failed Discontinued | |
MB-105 (PSCA) Details Prostate cancer, Multiple myeloma, Cancer | Failed Discontinued | |
MB-103 (HER2) Details Glioblastoma, Metastatic breast cancer to brain, Cancer | Failed Discontinued |